A Study of 28 Pediatric Patients With Drug Crystals Following Tosufloxacin Administration
- 25 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 34 (5)
Abstract
Background: Tosufloxacin (TFLX) is an oral fluoroquinolone antibiotic that has been reported to cause crystalluria and acute kidney injury. To clarify the clinical course of drug crystals after TFLX administration in children, we conducted a retrospective review of pediatric patients who developed drug crystals after receiving TFLX. Methods: This retrospective study included 28 pediatric patients aged 15 years or younger who were treated in the Department of Pediatrics at NTT Medical Center Sapporo, Japan, between January 1, 2016, and March 31, 2026, and in whom drug crystals were detected in urine sediment after TFLX administration. Results: The median age of the patients at diagnosis was 6.5 years (interquartile range: 4.4 to 8.2 y), and 11 patients (39%) were male. The median time to diagnosis after TFLX administration was 2 days (interquartile range: 1 to 3 d). Gastrointestinal symptoms, such as vomiting and abdominal pain, were observed in 6 patients (21%), and decreased appetite was observed in 3 patients (11%). All patients who had a known dosage received an appropriate dose of TFLX. Ten patients (36%) were diagnosed with acute kidney injury, and they improved within 3 to 5 days after discontinuing TFLX and replacing fluids. Conclusions: Despite the administration of the appropriate TFLX dosage, drug crystals were observed in the urine sediment 1 to 4 days after administration. When administering TFLX, it is important to be aware that drug crystals and acute kidney injury may occur. Discontinuing the drug can prevent progression of kidney injury.Keywords
This publication has 10 references indexed in Scilit:
- Macrolide-Resistant Mycoplasma pneumoniae Among Japanese Children from 2008 to 2024Microorganisms, 2025
- Renal and gastrointestinal complications following tosufloxacin therapy for suspected mycoplasma infection in a 10-year-old childCEN Case Reports, 2025
- Drug‐induced crystalluria attributable to tosufloxacin in childrenPediatrics International, 2022
- Crystalline nephropathy caused by tosufloxacinPediatrics International, 2016
- Clinical practice guideline for drug-induced kidney injury in Japan 2016: digest versionClinical and Experimental Nephrology, 2016
- Paraprotein–Related Kidney Disease: Evaluation and Treatment of Myeloma Cast NephropathyClinical Journal of the American Society of Nephrology, 2016
- KDIGO Clinical Practice Guidelines for Acute Kidney InjuryNephron Clinical Practice, 2012
- Ciprofloxacin Crystal NephropathyAmerican Journal of Kidney Diseases, 2007
- Modified RIFLE criteria in critically ill children with acute kidney injuryKidney International, 2007
- Pharmacokinetics and safety assessment of tosufloxacin tosilateJournal of Infection and Chemotherapy, 2002